Exploring taste function in patients with cognitive disorders
Official title: Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials
Run by Centre Hospitalier Universitaire Dijon · NCT05888961 · Data updated 2026-11-12
This study is testing how taste function changes in people with different levels of cognitive issues, including those with mild Alzheimer's, to see if it can help spot early signs of the disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 74 (estimated) |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Status | Recruiting |
| Started | June 12, 2023 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | September 25, 2026 |
| Trial ID | NCT05888961 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with varying stages of cognitive disorders, including healthy individuals and those with isolated cognitive complaints or diagnosed neurocognitive disorders.
✕Probably not a fit
Patients with severe cognitive impairment or those who do not meet the study's specific diagnostic criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to investigate gustatory function and its progression in four groups: healthy individuals, those with isolated cognitive complaints, individuals with minor neurocognitive disorders, and patients with mild to moderate Alzheimer-type major neurocognitive disorders. Participants will undergo subjective taste tests, gustatory evoked potential assessments, and nutritional evaluations through blood tests and body composition measurements. The goal is to identify early taste disorders associated with cognitive decline, potentially aiding in the early diagnosis and management of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management of Alzheimer's disease through the identification of taste disorders.
How similar studies have gone: While the exploration of gustatory function in cognitive disorders is a relatively novel approach, similar studies have shown promise in linking sensory functions to cognitive health.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Person who has given oral consent. * For patients with mild to moderate Alzheimer\'s disease, the primary caregiver and the patient will be asked to provide oral consent * Person of legal age * Body Mass Index (BMI) \< 30 kg/m². * For the healthy group: absence of cognitive complaints and normal neurological assessment * Patients meeting the criteria for isolated cognitive complaint: presence of cognitive complaint but normal neuropsychological evaluation * Patients meeting diagnostic criteria for minor cognitive impairment: imaging (brain MRI) and neuropsychological assessment with a Clinical Dementia Rating (CDR) score of 0.5 * Patients meeting diagnostic criteria for mild to moderate Alzheimer\'s disease: imaging (brain MRI), neuropsychobiological criteria (consultation with neuropsychological assessment, CSF biomarkers), MMSE score ≥ 20 and CDR score of 1 or 1.5 * Fasting for at least 2 hours before GEP measurement Exclusion Criteria: * MMSE score\<15 * Known COVID-19 infection within 6 months prior to inclusion * Person not affiliated to national health insurance system * Person under a legal protection measure (curatorship, guardianship) * Person subject to a measure of legal protection * Pregnant, parturient or breastfeeding women * Subjects with a pacemaker (contraindication to bioelectrical impedance measurement) * Adult unable to express consent or to perform cognitive tests. * Active smoker (\> 4 cigarettes per day on a regular basis) * Diabetic subject (type 1 or type 2) * Subject with acute or chronic ENT disease * Treatment interfering with gustation * Brain MRI showing another cause of neurocognitive disorder (except for vascular lesions Fazekas 1 accepted)
Where it's running
-
Chu Dijon Bourgogne
Dijon, France Recruiting
Study contacts
- Study coordinator: Agnès JACQUIN-PIQUES
- Email: agnes.jacquin-piques@chu-dijon.fr
- Phone: 03.80.29.37.54
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Photobiomodulation for thinking and memory problems after breast cancer chemotherapy
This trial will try photobiomodulation (a non-drug light therapy) to see if it helps thinking and memory problems in women who finished chemotherapy for breast cancer.
-
Cognitive rehabilitation for patients with multiple sclerosis
This study tests whether a computer-based cognitive treatment delivered online can help people with multiple sclerosis just as much as in-person therapy.
-
Daily nonalcoholic red-wine polyphenol drink to support thinking and mobility in early elderly adults
This 9-month test will see if drinking a daily nonalcoholic red-wine beverage rich in polyphenols improves cognition and muscle function in people aged 60–74.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.